122 related articles for article (PubMed ID: 6660921)
21. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
[TBL] [Abstract][Full Text] [Related]
22. Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer.
Göcze PM; Szabò DG; Than GN; Csaba IF; Keller G; Vahrson H; Bohn H
Strahlenther Onkol; 1991 Sep; 167(9):538-44. PubMed ID: 1833844
[TBL] [Abstract][Full Text] [Related]
23. Double antibody radioimmunoassay for monitoring metastatic breast cancer.
Schecter RL; Major PP; Kovac PE; Ishida M; Kovalik EC; Dion AS; Langleben A; Boileau G; Boos G; Panasci L
Br J Cancer; 1988 Sep; 58(3):362-7. PubMed ID: 3179189
[TBL] [Abstract][Full Text] [Related]
24. [A new perspective on axillary dissection in situations of metastatic sentinel node].
Zedníková I; Ňaršanská A; Hes O; Metelková A; Fiala O; Svoboda T
Rozhl Chir; 2017; 96(8):346-352. PubMed ID: 29058925
[TBL] [Abstract][Full Text] [Related]
25. Use of circulating pregnancy-specific beta 1 glycoprotein as a marker in carcinoma of the breast in women.
Rosen SW; Gail MH; Tormey DC
J Natl Cancer Inst; 1982 Nov; 69(5):1067-71. PubMed ID: 6982369
[TBL] [Abstract][Full Text] [Related]
26. Identity between the placental protein PP10 and the specific plasminogen activator inhibitor of placental type PAI-2.
Kiso U; Henschen A; Bohn H; Heimburger N; Radtke KP; Lecander I; Astedt B
Biochim Biophys Acta; 1991 May; 1074(1):74-8. PubMed ID: 2043683
[TBL] [Abstract][Full Text] [Related]
27. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
Sopik V; Narod SA
Breast Cancer Res Treat; 2018 Aug; 170(3):647-656. PubMed ID: 29693227
[TBL] [Abstract][Full Text] [Related]
28. Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence.
Jeschke U; Mylonas I; Kunert-Keil C; Dazert E; Shabani N; Werling M; Kuhn C; Janni W; Gerber B; Friese K
Oncol Rep; 2005 Mar; 13(3):413-9. PubMed ID: 15706409
[TBL] [Abstract][Full Text] [Related]
29. Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance.
Kuang YH; Liu YJ; Tang LL; Wang SM; Yan GJ; Liao LQ
Hong Kong Med J; 2018 Jun; 24(3):252-260. PubMed ID: 29807951
[TBL] [Abstract][Full Text] [Related]
30. Haemostasis activation markers in plasma of patients with benign and malignant gynaecological tumours: a pilot study.
van Wersch JW; Peters C; Ubachs HM
Eur J Clin Chem Clin Biochem; 1995 Apr; 33(4):225-9. PubMed ID: 7626694
[TBL] [Abstract][Full Text] [Related]
31. [Current concepts of the surgical management of gynaecological tumours (author's transl)].
Janisch H
Wien Klin Wochenschr; 1981 Mar; 93(6):175-8. PubMed ID: 7281692
[TBL] [Abstract][Full Text] [Related]
32. Possible synthesis of pregnancy-'specific' beta-1-glycoprotein (sp1) and placenta-'specific' tissue proteins (PP10,PP12) by human and cynomolgus monkey leukocytes.
Inaba N; Renk T; Ax W; Schottler S; Weinmann E; Bohn H
Acta Haematol; 1981; 66(1):35-8. PubMed ID: 6794297
[TBL] [Abstract][Full Text] [Related]
33. [Cathepsin D in primary breast cancer in correlation with various prognostic factors].
Rempen A; Caffier H
Geburtshilfe Frauenheilkd; 1991 Apr; 51(4):272-5. PubMed ID: 1650323
[TBL] [Abstract][Full Text] [Related]
34. Tumor markers (pregnancy protein 1, placental-specific tissue protein 10, placental-specific tissue protein 12, alpha1-fetoprotein) in patients with bronchial carcinoma.
Briese V; Szabo DG; Than GN; Willroth PO; Brieses J
Anticancer Res; 2005; 25(3A):1667-70. PubMed ID: 16033079
[TBL] [Abstract][Full Text] [Related]
35. Coagulation factor XIII in plasma of patients with benign and malignant gynaecological tumours.
van Wersch JW; Peters C; Ubachs JM
Eur J Clin Chem Clin Biochem; 1994 Sep; 32(9):681-4. PubMed ID: 7865623
[TBL] [Abstract][Full Text] [Related]
36. [Plasmatic glycoproteins in malignant neoplasms of the female genital system].
Torre GC; Salvatores D; Azzarini V
Arch Ostet Ginecol; 1970; 75(1):78-92. PubMed ID: 5459103
[No Abstract] [Full Text] [Related]
37. The pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG). A tumour marker?
Bauer HW
Klin Wochenschr; 1981 Feb; 59(4):149-55. PubMed ID: 7015001
[TBL] [Abstract][Full Text] [Related]
38. Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease.
Bremner RD; Nisbet AD; Herriot R; Horne CH; McArdle C; Crawford D; Bohn H
Oncodev Biol Med; 1981; 2(1-2):55-62. PubMed ID: 6975467
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
40. Placental protein 4 as a possible tumor marker in ovarian tumors.
Göcze PM; Szabò DG; Than GN; Krommer KF; Csaba IF; Bohn H
Gynecol Obstet Invest; 1991; 32(2):107-11. PubMed ID: 1836196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
